JAK Inhibition in STAT1 Gain-of-Function–Mediated Treatment-Resistant Autoimmune Hepatitis
- 18 January 2024
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 390 (3) , 284-286
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- JAKs and STATs from a Clinical Perspective: Loss-of-Function Mutations, Gain-of-Function Mutations, and Their Multidimensional ConsequencesJournal of Clinical Immunology, 2023
- Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutationsJournal of Allergy and Clinical Immunology, 2018
- Diagnosis and Management of Pediatric Autoimmune Liver DiseaseJournal of Pediatric Gastroenterology and Nutrition, 2018
- Dysfunctional CD39POS regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitisHepatology, 2013
- Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasisJournal of Experimental Medicine, 2011